Min-Han Tan: The era of liquid biopsy is truly emerging and moving beyond blood

Min-Han Tan, Founding CEO at Lucence, shared a post by Lucence on LinkedIn, adding the following:

“The era of liquid biopsy is truly emerging, and moving beyond blood.

Liquid biopsies using blood are now routine and Medicare-covered for cancer patients.

Conclusive evidence is also available that liquid biopsy NGS is useful for selecting treatments when profiling fluids such as pleural effusion and CSF.

But there’s a big gap to mass cancer screening through blood. Millions of people worldwide are either terrified of blood draw, or not have a convenient facility nearby.

Very glad to partner DxD Hub and Singapore public hospitals in developing a solution to benefit the world!”

Quoting Lucence’s post:

“Screening for multiple cancers using urine can help millions of people who either fear or do not have easy access to phlebotomy.

We’re glad to partner with DxD Hub – Diagnostics Development Hub and Singapore hospitals to expand application of multi-cancer liquid biopsy technology to this important sample type.

Exciting times ahead!”

Source: Min-Han Tan/LinkedIn and Lucence/LinkedIn